JP2017537892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537892A5 JP2017537892A5 JP2017523286A JP2017523286A JP2017537892A5 JP 2017537892 A5 JP2017537892 A5 JP 2017537892A5 JP 2017523286 A JP2017523286 A JP 2017523286A JP 2017523286 A JP2017523286 A JP 2017523286A JP 2017537892 A5 JP2017537892 A5 JP 2017537892A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- agent
- cancer
- activity
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 34
- 239000005557 antagonist Substances 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 31
- 229940122315 Notch pathway inhibitor Drugs 0.000 claims description 30
- 108700041286 delta Proteins 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 239000002955 immunomodulating agent Substances 0.000 claims description 25
- 108010070047 Notch Receptors Proteins 0.000 claims description 23
- 102000005650 Notch Receptors Human genes 0.000 claims description 23
- 229940044551 receptor antagonist Drugs 0.000 claims description 22
- 239000002464 receptor antagonist Substances 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 230000002708 enhancing effect Effects 0.000 claims description 10
- 239000000556 agonist Substances 0.000 claims description 8
- 102000002698 KIR Receptors Human genes 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 5
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 4
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 4
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 102000017578 LAG3 Human genes 0.000 claims description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 4
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000009464 antigen specific memory response Effects 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 210000003289 regulatory T cell Anatomy 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 230000002459 sustained effect Effects 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 229940123494 CD20 antagonist Drugs 0.000 claims description 2
- 229940121697 CD27 agonist Drugs 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 229940123205 CD28 agonist Drugs 0.000 claims description 2
- 229940123189 CD40 agonist Drugs 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 229940123828 CD80 antagonist Drugs 0.000 claims description 2
- 229940121850 CD86 agonist Drugs 0.000 claims description 2
- 229940121764 CD86 antagonist Drugs 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101000978766 Homo sapiens Neurogenic locus notch homolog protein 1 Proteins 0.000 claims description 2
- 101000577199 Homo sapiens Neurogenic locus notch homolog protein 2 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 2
- 229940123751 PD-L1 antagonist Drugs 0.000 claims description 2
- 229940121678 PD-L2 antagonist Drugs 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 229940123803 TIM3 antagonist Drugs 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 102000044457 human DLL4 Human genes 0.000 claims description 2
- 102000045609 human NOTCH1 Human genes 0.000 claims description 2
- 102000046883 human NOTCH2 Human genes 0.000 claims description 2
- 102000058223 human VEGFA Human genes 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 210000002536 stromal cell Anatomy 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- 239000008177 pharmaceutical agent Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 101000577202 Homo sapiens Neurogenic locus notch homolog protein 3 Proteins 0.000 description 1
- 229940123309 Immune checkpoint modulator Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073634P | 2014-10-31 | 2014-10-31 | |
| US62/073,634 | 2014-10-31 | ||
| US201562127172P | 2015-03-02 | 2015-03-02 | |
| US62/127,172 | 2015-03-02 | ||
| US201562192133P | 2015-07-14 | 2015-07-14 | |
| US62/192,133 | 2015-07-14 | ||
| US201562242567P | 2015-10-16 | 2015-10-16 | |
| US62/242,567 | 2015-10-16 | ||
| PCT/US2015/058327 WO2016070051A2 (en) | 2014-10-31 | 2015-10-30 | Combination therapy for treatment of disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537892A JP2017537892A (ja) | 2017-12-21 |
| JP2017537892A5 true JP2017537892A5 (cg-RX-API-DMAC7.html) | 2018-12-06 |
| JP6827415B2 JP6827415B2 (ja) | 2021-02-10 |
Family
ID=55858530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523286A Active JP6827415B2 (ja) | 2014-10-31 | 2015-10-30 | 疾患の処置のための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20160176962A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3212233B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6827415B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107530419B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015338974B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2966042A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3212233T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2808153T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX382902B (cg-RX-API-DMAC7.html) |
| PT (1) | PT3212233T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016070051A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
| CN107722122B (zh) | 2011-09-23 | 2022-05-27 | 昂考梅德药品有限公司 | Vegf/dll4结合剂及其应用 |
| CN104994873B (zh) * | 2012-10-04 | 2017-12-22 | 达纳－法伯癌症研究所公司 | 人单克隆抗‑pd‑l1抗体和使用方法 |
| EP2912063A1 (en) * | 2012-10-23 | 2015-09-02 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| ES2845609T3 (es) | 2013-05-02 | 2021-07-27 | Anaptysbio Inc | Anticuerpos dirigidos contra muerte programada-1 (PD-1) |
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| PT3212233T (pt) | 2014-10-31 | 2020-07-16 | Oncomed Pharm Inc | Terapia combinada para o tratamento de doenças |
| US11275080B2 (en) | 2014-11-05 | 2022-03-15 | The Regents Of The University Of California | Methods for stratifying non-responders to therapies that block PD1/PDL1 axis |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| IL292449B2 (en) | 2015-03-13 | 2024-02-01 | Cytomx Therapeutics Inc | Nucleic acids encoding anti-pdl1 antibodie and methods of producing same |
| WO2017011580A2 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| ES2968074T3 (es) | 2015-09-23 | 2024-05-07 | Mereo Biopharma 5 Inc | Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino |
| EP3442528B1 (en) | 2016-04-12 | 2021-05-26 | Eli Lilly and Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating ovarian cancer |
| TWI794171B (zh) * | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI755395B (zh) * | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| JP7194022B2 (ja) * | 2016-05-20 | 2022-12-21 | イーライ リリー アンド カンパニー | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 |
| AU2017278193B9 (en) * | 2016-06-10 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Anti-GITR antibodies and uses thereof |
| WO2018009904A2 (en) * | 2016-07-08 | 2018-01-11 | Tumeh Paul C | Compositions and treatment methods for cancer immunotherapy |
| EP4512829A3 (en) | 2016-07-14 | 2025-06-11 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| WO2018027524A1 (en) * | 2016-08-09 | 2018-02-15 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibody formulation |
| WO2018045177A1 (en) | 2016-09-01 | 2018-03-08 | Chimera Bioengineering, Inc. | Gold optimized car t-cells |
| US20190201526A1 (en) * | 2016-09-07 | 2019-07-04 | The Wistar Institute Of Anatomy And Biology | Methods and Compositions for Treating Cancers by Inhibiting Estrogen Signaling in Myeloid-Derived Suppressor Cells |
| CA3035262A1 (en) * | 2016-09-16 | 2018-03-22 | Tina Christine Lavranos | Antibody and checkpoint inhibitor combination therapy |
| EP3534950A4 (en) | 2016-11-01 | 2020-05-06 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| CN110234319B (zh) * | 2016-11-23 | 2022-09-27 | 转化药物开发有限责任公司 | 苯甲酰胺和活性化合物的组合物及其使用方法 |
| WO2018102769A1 (en) * | 2016-12-01 | 2018-06-07 | Bluelink Pharmaceuticals, Inc. | Treatment of cancer |
| MX2019008207A (es) | 2017-01-09 | 2019-12-11 | Tesaro Inc | Métodos para tratar el cáncer con anticuerpos anti-pd-1. |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US12006354B2 (en) | 2017-05-24 | 2024-06-11 | Novartis Ag | Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| WO2019023786A1 (en) * | 2017-08-01 | 2019-02-07 | University Health Network | COMBINED THERAPIES FOR THE INHIBITION OF TTK PROTEIN KINASE |
| KR20200044899A (ko) | 2017-08-28 | 2020-04-29 | 브리스톨-마이어스 스큅 컴퍼니 | 암의 치료 및 진단을 위한 tim-3 길항제 |
| BR112020008812A2 (pt) | 2017-11-06 | 2020-10-27 | Juno Therapeutics Inc | combinação de terapia celular e um inibidor de gama secretase |
| WO2019140229A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| US11110125B2 (en) | 2018-02-13 | 2021-09-07 | Chimera Bioengineering, Inc. | Coordinating gene expression using RNA destabilizing elements |
| BR112020022654A2 (pt) * | 2018-05-06 | 2021-03-09 | Ayala Pharmaceuticals Inc. | Composições de combinação que compreendem compostos de bisfluoroalquil-1,4-benzodiazepinona e métodos de uso das mesmas |
| CN108753833B (zh) * | 2018-05-28 | 2021-12-03 | 上海海洋大学 | 斑马鱼notch3基因突变体的制备方法 |
| WO2020102577A1 (en) * | 2018-11-16 | 2020-05-22 | The Brigham And Women's Hospital, Inc. | Antibodies blocking dll4-mediated notch signaling |
| AU2020287343A1 (en) * | 2019-06-05 | 2021-12-09 | Southern Research Institute | Thiarabine- and thiarabine prodrug-based treatments |
| US20210046117A1 (en) | 2019-08-18 | 2021-02-18 | Chimera Bioengineering, Inc. | Combination Therapy with Gold Controlled Transgenes |
| IL296043A (en) | 2020-03-06 | 2022-10-01 | Regeneron Pharma | Anti-gitro antibodies and their uses |
| WO2022125392A1 (en) * | 2020-12-09 | 2022-06-16 | Chimera Bioengineering, Inc. | Compositions and methods for activating t-cells |
| WO2022260968A1 (en) * | 2021-06-10 | 2022-12-15 | Chimera Bioengineering, Inc. | Compositions and methods for activating natural killer cells |
| EP4417619A4 (en) * | 2021-10-12 | 2025-12-03 | Palmira Biopharma Llc | NUCLEOTIDE SEQUENCE CODING FOR A FUSION PROTEIN |
| TW202440636A (zh) | 2023-03-21 | 2024-10-16 | 美商傳記５５有限公司 | Ｃｄ１９／ｃｄ３８多特異性抗體 |
Family Cites Families (167)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| IL101728A (en) | 1991-05-03 | 2007-08-19 | Univ Yale | Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them |
| US20050112121A1 (en) | 1992-04-30 | 2005-05-26 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| US5786158A (en) | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| WO1997001571A1 (en) | 1995-06-28 | 1997-01-16 | Imperial Cancer Research Technology, Ltd. | Nucleotide and protein sequences of vertebrate delta genes and methods based thereon |
| US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| JPH09124697A (ja) | 1995-11-01 | 1997-05-13 | Toagosei Co Ltd | ペプチド及びモノクローナル抗体 |
| US6337387B1 (en) | 1995-11-17 | 2002-01-08 | Asahi Kasei Kabushiki Kaisha | Differentiation-suppressive polypeptide |
| US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU6952498A (en) | 1997-04-04 | 1998-10-30 | Millenium Pharmaceuticals, Inc. | Novel human delta3 compositions and therapeutic and diagnostic uses therefor |
| US6121045A (en) | 1997-04-04 | 2000-09-19 | Millennium Biotherapeutics, Inc. | Human Delta3 nucleic acid molecules |
| US20030180784A1 (en) | 1997-04-04 | 2003-09-25 | Millennium Pharmaceuticals, Inc. | Novel human Delta3 compositions and therapeutic and diagnostic uses therefor |
| US20060122373A1 (en) | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| SI1325932T1 (cg-RX-API-DMAC7.html) | 1997-04-07 | 2005-08-31 | Genentech Inc | |
| US20070059302A1 (en) | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| JP4171528B2 (ja) | 1997-05-14 | 2008-10-22 | 旭化成株式会社 | 新規な分化抑制剤 |
| WO1998057621A1 (en) | 1997-06-18 | 1998-12-23 | The Trustees Of Columbia University In The City Ofnew York | Angiogenic modulation by notch signal transduction |
| US6004528A (en) | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
| AU4870599A (en) | 1998-07-27 | 2000-02-21 | Amgen, Inc. | Delta-related polypeptides |
| WO2000064946A2 (en) | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| CA2494705A1 (en) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20110131679A2 (en) | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| US20020028488A1 (en) | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| US6689744B2 (en) | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
| US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| JP2004537314A (ja) | 2001-07-25 | 2004-12-16 | ロランティス リミテッド | ノッチシグナル伝達モジュレーターを検出する方法 |
| AU2002317333C1 (en) | 2001-08-01 | 2009-06-25 | University Of Bristol | VEGF isoform |
| EP1446424A2 (en) | 2001-11-14 | 2004-08-18 | Lorantis Limited | Composition comprising inhibitors of the notch signalling pathway for the modulation of the immune system |
| EP1448599A2 (en) | 2001-11-14 | 2004-08-25 | Lorantis Limited | Inhibitors of the notch signalling pathway for use in the treatment of cancer |
| US20050137130A1 (en) | 2001-11-14 | 2005-06-23 | Bodmer Mark W. | Medical treatment |
| JP2005511754A (ja) | 2001-12-07 | 2005-04-28 | リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 乳癌幹細胞の予測的同定および特徴づけ |
| AUPS054702A0 (en) * | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
| US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| GB0218879D0 (en) | 2002-08-14 | 2002-09-25 | Lorantis Ltd | Medical treatment |
| JP2006515177A (ja) | 2002-09-10 | 2006-05-25 | ロランティス リミテッド | Ｎｏｔｃｈリガンドタンパク質を含む医薬組成物及び医学的処置 |
| CA2519875C (en) | 2003-06-06 | 2014-01-14 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with vegf inhibitors |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| WO2005014618A2 (en) | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| FR2859725B1 (fr) | 2003-09-16 | 2006-03-10 | Neovacs | Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine |
| CN101102786A (zh) | 2004-06-10 | 2008-01-09 | 瑞泽恩制药公司 | 施用并利用vegf抑制剂治疗人类癌症的方法 |
| WO2005124364A1 (en) | 2004-06-15 | 2005-12-29 | F. Hoffmann-La Roche Ag | The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication |
| US20050281822A1 (en) | 2004-06-18 | 2005-12-22 | Cedarbaum Jesse M | Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion |
| EP1615036B1 (en) | 2004-07-07 | 2007-09-19 | F.Hoffmann-La Roche Ag | Multimarker panel for diabetes type 1 and 2 |
| US20060204493A1 (en) | 2004-09-02 | 2006-09-14 | Genentech, Inc. | Heteromultimeric molecules |
| US20080254031A1 (en) | 2004-09-09 | 2008-10-16 | Exonhit Therapeutics Sa | Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis |
| US8911726B2 (en) | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
| US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
| US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| AU2005302846A1 (en) | 2004-11-10 | 2006-05-18 | Hubrecht Laboratorium | Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation |
| EP1812064A4 (en) | 2004-11-19 | 2009-07-08 | Cornell Res Foundation Inc | USE OF VASCULAR ENDOTHEL GROWTH FACTOR RECEPTOR 1+ CELLS IN THE TREATMENT AND MONITORING OF CANCER AND SCREENING IN CHEMOTHERAPY |
| US7432107B2 (en) | 2005-01-24 | 2008-10-07 | Roche Diagnostics Operations, Inc. | Cardiac hormones for assessing cardiovascular risk |
| EP1853298A2 (en) | 2005-02-11 | 2007-11-14 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| US9296816B2 (en) | 2005-04-15 | 2016-03-29 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| EP1896582A4 (en) * | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| BRPI0611009A2 (pt) | 2005-06-02 | 2010-08-10 | Galaxy Biotech Llc | usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização |
| CN104356236B (zh) * | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CN101237880B (zh) | 2005-08-12 | 2011-09-21 | 瑞泽恩制药公司 | 通过vegf拮抗剂的皮下给药治疗疾病 |
| US7906116B2 (en) | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| CA2621226A1 (en) | 2005-09-01 | 2007-03-08 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| AU2006308847C1 (en) | 2005-10-31 | 2012-05-10 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
| PL1962895T3 (pl) | 2005-12-16 | 2013-06-28 | Regeneron Pharma | Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów |
| WO2007098387A2 (en) | 2006-02-17 | 2007-08-30 | Gilead Colorado, Inc. | Antihypertensive therapy |
| WO2007103114A2 (en) | 2006-03-07 | 2007-09-13 | The Brigham & Women's Hospital, Inc. | Notch inhibition in the treatment or prevention of atherosclerosis |
| US7354582B2 (en) | 2006-03-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Use of VEGF antagonists for the treatment of malignant gliomas |
| EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
| WO2007143689A2 (en) | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| SG175615A1 (en) * | 2006-06-06 | 2011-11-28 | Genentech Inc | Anti-dll4 antibodies and methods using same |
| EP2032166B1 (en) | 2006-06-13 | 2013-04-10 | OncoMed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| ES2398253T3 (es) | 2006-08-07 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Uso de antagonistas de DII4 en lesión isquémica o insuficiencia vascular |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| UA110315C2 (uk) * | 2006-09-29 | 2015-12-25 | Oncomed Pharm Inc | Композиція та спосіб лікування раку |
| ME02371B (me) | 2006-09-29 | 2016-06-20 | Oncomed Pharm Inc | Sastojci i postupci za dijagnstikovanje i tretman raka |
| US20110076279A1 (en) | 2006-10-20 | 2011-03-31 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| US8466154B2 (en) | 2006-10-27 | 2013-06-18 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to wrapping of dehydrons |
| WO2008070042A2 (en) | 2006-12-04 | 2008-06-12 | Medimmune, Inc. | High potency recombinant antibodies, methods for producing them and use in cancer therapy |
| EP2099489B1 (en) | 2006-12-11 | 2014-05-21 | Genentech, Inc. | Compositions and methods for treating a neoplasm |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| SG10201503407WA (en) | 2006-12-19 | 2015-06-29 | Genentech Inc | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| EP2120996A2 (en) | 2006-12-20 | 2009-11-25 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| WO2008091222A1 (en) | 2007-01-26 | 2008-07-31 | Bioinvent International Ab | Dll4 signaling inhibitors and uses thereof |
| US20120040025A9 (en) | 2007-05-04 | 2012-02-16 | Currie Mark G | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention |
| GB0709333D0 (en) | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| CA2702637A1 (en) | 2007-10-22 | 2009-04-30 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| WO2009053987A1 (en) | 2007-10-25 | 2009-04-30 | University Of Bristol | Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf) |
| AR069501A1 (es) | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
| WO2009075565A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Methods for controlling vasculogenesis |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| US8557965B2 (en) | 2008-04-07 | 2013-10-15 | Ablynx N.V. | Single variable domains against notch pathway members |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| PT2307051E (pt) * | 2008-07-08 | 2015-05-21 | Oncomed Pharm Inc | Antagonistas e agentes de ligação a notch e métodos de utilização dos mesmos |
| WO2010010153A1 (en) | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Identification of subjects being susceptible to anti-angiogenesis therapy |
| EP2324358A1 (en) | 2008-07-23 | 2011-05-25 | F. Hoffmann-La Roche AG | Monitoring anti-angiogenesis therapy |
| EP2328919A2 (en) * | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| CN102264763B (zh) | 2008-09-19 | 2016-04-27 | 米迪缪尼有限公司 | 定向于dll4的抗体及其用途 |
| CA2742968C (en) | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| PT2376116E (pt) | 2008-12-12 | 2016-02-24 | Boehringer Ingelheim Int | Anticorpos anti-igf |
| BRPI1006438A2 (pt) | 2009-04-20 | 2016-09-27 | Genentech Inc | terapia adjuvante de cancer |
| WO2010124009A2 (en) | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| CA2759233C (en) | 2009-04-27 | 2019-07-16 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
| CA2766166A1 (en) | 2009-07-08 | 2011-01-13 | Amgen Inc. | Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering |
| WO2011025964A2 (en) | 2009-08-29 | 2011-03-03 | Abbott Laboratories | Therapeutic dll4 binding proteins |
| NZ598929A (en) | 2009-09-01 | 2014-05-30 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
| US20110172398A1 (en) | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| US8883145B2 (en) * | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
| JP2013508308A (ja) | 2009-10-23 | 2013-03-07 | ガーバン インスティテュート オブ メディカル リサーチ | 修飾可変ドメイン分子、ならびにその産生および使用方法 |
| EP2493497A4 (en) | 2009-11-01 | 2013-07-24 | Brigham & Womens Hospital | NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME |
| JP2013512278A (ja) | 2009-12-01 | 2013-04-11 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｋ−ｒａｓ変異を含んだ癌を処置するための方法 |
| AU2011205316B2 (en) * | 2010-01-13 | 2015-05-28 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| JP6034696B2 (ja) | 2010-02-12 | 2016-11-30 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ポリペプチド発現細胞の同定及び単離の方法 |
| BR112012021941A2 (pt) | 2010-03-02 | 2022-02-01 | Abbvie Inc | Proteínas terapêuticas de ligação a dll4 |
| ES2630328T3 (es) | 2010-08-23 | 2017-08-21 | Board Of Regents, The University Of Texas System | Anticuerpos anti-OX40 y procedimientos de uso de los mismos |
| US8551479B2 (en) * | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| US20130323265A1 (en) | 2010-11-15 | 2013-12-05 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with dll4 antagonists |
| JP5889800B2 (ja) | 2010-12-01 | 2016-03-22 | キッコーマン株式会社 | 大腸菌形質転換体、それを用いたフラビン結合型グルコースデヒドロゲナーゼの製造方法、および、変異型フラビン結合型グルコースデヒドロゲナーゼ |
| TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯二氮呯酮化合物 |
| JP2014523421A (ja) | 2011-06-17 | 2014-09-11 | ハリス，エイドリアン，エル． | 抗ｄｌｌ４抗体を使用して腫瘍治療における放射線に対する反応を増大させる方法 |
| CN107722122B (zh) * | 2011-09-23 | 2022-05-27 | 昂考梅德药品有限公司 | Vegf/dll4结合剂及其应用 |
| CN104105702B (zh) * | 2011-11-16 | 2016-11-23 | 昂考梅德药品有限公司 | 人notch受体突变及其应用 |
| EP2855522A1 (en) | 2012-02-03 | 2015-04-08 | MedImmune Limited | Process for reducing antibody aggregate levels and antibodies produced thereby |
| EA037351B8 (ru) * | 2012-05-15 | 2021-04-29 | Бристол-Майерс Сквибб Компани | Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4 |
| JP2015517529A (ja) * | 2012-05-16 | 2015-06-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｎｏｔｃｈ２／３抗体によって癌を治療するための方法 |
| WO2014062245A2 (en) | 2012-05-31 | 2014-04-24 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind dll-4 |
| AR092325A1 (es) | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| KR101535341B1 (ko) | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| US9695233B2 (en) | 2012-07-13 | 2017-07-04 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
| KR20150060686A (ko) | 2012-09-28 | 2015-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF 제제를 포함하는 약제학적 조합물 |
| CN104994873B (zh) | 2012-10-04 | 2017-12-22 | 达纳－法伯癌症研究所公司 | 人单克隆抗‑pd‑l1抗体和使用方法 |
| AU2013337811A1 (en) | 2012-10-31 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| BR112015009961B1 (pt) | 2012-11-01 | 2020-10-20 | Abbvie Inc. | proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende |
| TW201438736A (zh) | 2012-11-14 | 2014-10-16 | Regeneron Pharma | 以ｄｌｌ４拮抗劑治療卵巢癌之方法 |
| ES2845609T3 (es) | 2013-05-02 | 2021-07-27 | Anaptysbio Inc | Anticuerpos dirigidos contra muerte programada-1 (PD-1) |
| WO2015130751A1 (en) | 2014-02-26 | 2015-09-03 | Medimmune, Llc | Methods of treatment with dll4 antagonists |
| MA39313B1 (fr) * | 2014-03-11 | 2018-12-31 | Regeneron Pharma | Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers |
| BR112017000130A2 (pt) | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
| PT3212233T (pt) | 2014-10-31 | 2020-07-16 | Oncomed Pharm Inc | Terapia combinada para o tratamento de doenças |
| ES2968074T3 (es) * | 2015-09-23 | 2024-05-07 | Mereo Biopharma 5 Inc | Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino |
| WO2020012447A1 (en) | 2018-07-13 | 2020-01-16 | Composite Interceptive Med-Science Laboratories Private Limited | Polyherbal formulation and method for production thereof |
-
2015
- 2015-10-30 PT PT158561001T patent/PT3212233T/pt unknown
- 2015-10-30 CA CA2966042A patent/CA2966042A1/en active Pending
- 2015-10-30 WO PCT/US2015/058327 patent/WO2016070051A2/en not_active Ceased
- 2015-10-30 ES ES15856100T patent/ES2808153T3/es active Active
- 2015-10-30 AU AU2015338974A patent/AU2015338974B2/en active Active
- 2015-10-30 DK DK15856100.1T patent/DK3212233T3/da active
- 2015-10-30 CN CN201580068724.2A patent/CN107530419B/zh active Active
- 2015-10-30 US US14/928,271 patent/US20160176962A1/en not_active Abandoned
- 2015-10-30 JP JP2017523286A patent/JP6827415B2/ja active Active
- 2015-10-30 MX MX2017005258A patent/MX382902B/es unknown
- 2015-10-30 EP EP15856100.1A patent/EP3212233B1/en active Active
-
2018
- 2018-02-06 US US15/889,532 patent/US11046760B2/en active Active
-
2021
- 2021-05-26 US US17/330,716 patent/US20210403553A1/en not_active Abandoned
-
2024
- 2024-06-28 US US18/758,255 patent/US20250179169A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537892A5 (cg-RX-API-DMAC7.html) | ||
| Yonezawa et al. | Boosting cancer immunotherapy with anti-CD137 antibody therapy | |
| WO2016070051A4 (en) | Combination therapy for treatment of disease | |
| Aranda et al. | Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy | |
| AU2014351308B2 (en) | Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy | |
| CN107847587B (zh) | Cd30×cd16抗体与pd-1拮抗剂的联合药物 | |
| US20230111786A1 (en) | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent | |
| EP2970473B1 (en) | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use | |
| JP2016525117A5 (cg-RX-API-DMAC7.html) | ||
| JP2020503273A5 (cg-RX-API-DMAC7.html) | ||
| JP2019513725A5 (cg-RX-API-DMAC7.html) | ||
| JP2015508816A5 (cg-RX-API-DMAC7.html) | ||
| JP2020522495A5 (cg-RX-API-DMAC7.html) | ||
| JP2017532952A5 (cg-RX-API-DMAC7.html) | ||
| JP2021529741A (ja) | がん治療 | |
| JP2017534633A5 (cg-RX-API-DMAC7.html) | ||
| WO2016126781A4 (en) | Tnfrsf-binding agents and uses thereof | |
| JP2020500181A5 (cg-RX-API-DMAC7.html) | ||
| Patnaik et al. | Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial | |
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| JP2018503365A5 (cg-RX-API-DMAC7.html) | ||
| JP2017500057A5 (cg-RX-API-DMAC7.html) | ||
| JP2015529641A5 (cg-RX-API-DMAC7.html) | ||
| JP2015536933A5 (cg-RX-API-DMAC7.html) | ||
| KR20220007593A (ko) | 암 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용 |